About
Highly accomplished Drug Metabolism and Pharmacokinetics (DMPK) Scientist with over 18…
Activity
1K followers
-
Biplab Das posted thisRecent review -In Vitro and In Vivo Metabolism Studies -Biplab Das and Chandra Prakash published in Drug Discovery and Evaluation : Safety and Pharmacokinetic Assay (2023) Despite major strides in the understanding of drug metabolic processes, knowledge in several areas is still lacking, and predictive tools, while significantly improved, need further enhancement. In silico tools are improving with better ability to predict labile metabolic sites. The lack of available data in humans in early drug discovery stages makes it difficult to have well validated, rapid, in vitro ADME tools, in complement with relevant in vivo preclinical animal models that can accurately predict the ADME and safety of an NME in humans. In recent years, artificial intelligence (AI) and machine learning (ML) have also emerged as an indispensable tool in preclinical discovery and ADME/Tox to help teams make the right decision. Taken together, drug metabolism as a discipline is a critical component in drug discovery and development, contributing significantly to the process of identifying new drug molecules and bringing them to patients with unmet medical needs. This chapter describes, in detail, the utility and the challenges of these tools both with in vitro and in vivo metabolism studies that are used to design better molecules that have properties that include lower systemic clearance, and also assist in the selection of nonclinical species for use in safety assessment studies in preclinical development. Additionally, these tools aid in the understanding of reactive metabolites to avoid idiosyncratic adverse drug reactions. Practical case examples are provided.
Biplab Das commented on a post
4mo
Congratulations! 🎉
-
Biplab Das liked thisBiplab Das liked thisDon’t burn bridges. Build relationships that last beyond the job.
-
Biplab Das liked thisBiplab Das liked thisA dream Ratan Tata nurtured for years has finally taken flight. India’s first Made-in-India C-295 military aircraft is now in the skies, a major milestone in the country's journey from importing technology to building it. Watch the video to see how vision, perseverance, and Indian innovation came together to make history. #RatanTata #MakeInIndia #Innovation #Aerospace A dream Ratan Tata nurtured for years has finally taken flight. India’s first Made-in-India C-295 military aircraft is now in the skies, a major milestone in the country's journey from importing technology to building it. Watch the video to see how vision, perseverance, and Indian innovation came together to make history. #RatanTata #MakeInIndia #Innovation #Aerospace
-
Biplab Das liked thisBiplab Das liked thisI'm excited to share that we are growing our scientific team at InSilicoMinds. As we continue expanding our work in PBPK modeling, pharmacometrics, biosimilars, complex generics, AI-driven drug development, and regulatory-grade Modeling & Simulation, we are looking for passionate scientists who want to work on impactful and challenging projects for global pharmaceutical companies. If you enjoy solving complex scientific problems and want to help shape the future of Model Informed Drug Development, I would love to hear from you. Please review the job posting below and apply if interested, or feel free to share with someone in your network who may be a great fit. #Hiring #PBPK #Pharmacometrics #DrugDevelopment #ModelingAndSimulation #MIDD #InSilicoMinds
-
Biplab Das liked thisBiplab Das liked thisAfter more than three decades in drug discovery and development, I am stepping into retirement with a full heart, deep gratitude, and genuine excitement for what lies ahead. I feel incredibly fortunate to have spent my career doing work that I truly loved, alongside people who inspired me every day. My time at Bristol Myers Squibb and Agios Pharmaceuticals shaped me not only as a scientist and leader, but as a lifelong learner. I had the privilege of contributing to programs that moved from early discovery to patients, but even more importantly, I was part of teams that believed deeply in collaboration, rigor, and purpose. I owe so much to my mentors, who challenged me, trusted me, and generously shared their wisdom over the years. I am equally grateful to the many colleagues and cross‑functional partners around the world who taught me something new every day. Science is never a solo endeavor, and I have been lucky to work with people who made even the hardest problems feel solvable—together. One of the greatest joys of my career has been the opportunity to build teams and invest in the growth of junior scientists. Watching them develop confidence, curiosity, and scientific judgment—and then go on to do amazing things of their own—has been deeply rewarding and something I will always cherish. Later in my career, gaining a CRO and integrated drug discovery perspective from Syngene international, including building end‑to‑end discovery capabilities across the US and India, broadened my view and reinforced for me the importance of integration and partnership with academia and never stopping learning. As I begin this next chapter, I’m looking forward to slowing down just enough to savor it. I plan on giving back through volunteering; staying intellectually engaged and connected to the scientific community in thoughtful ways; spending lots of precious time with my granddaughter and finally making space to learn new skills that I never quite found time for during a wonderfully full career. Though this chapter is coming to a close, the relationships and friendships endure. I hope to stay connected and would be delighted to hear from you as our paths continue to cross in new ways. Thank you to everyone who has been part of my journey—you made this career far more meaningful than I ever imagined. Here’s to lifelong learning, new beginnings, and a little more time for what matters most.
-
Biplab Das liked thisBiplab Das liked thisHappy to share the results of this collaboration with the brilliant Dr. Jinbin Pan and colleagues at Tianjin Medical University. Ultrasmall gold nanoclusters enable more sensitive imaging of the kidneys compared to iodinated contrast which we hope translates into less risk of contrast induced nephropathy. Importantly, differences in renal pharmacokinetics with the gold nanoclusters demonstrated disease mechanism-specific imaging signatures and distinct time-attenuation behaviors that allowed for the noninvasive characterization of different types of kidney injury. Interesting implications for photon counting CT. The Martinos Center for Biomedical Imaging, MGB Radiology Research #kidneys #CT #PCCTContrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunctionContrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction
-
Biplab Das liked thisBiplab Das liked thisExciting news from ENSEM! 🎉 The U.S. FDA has cleared our IND application for ETX-929 — a potentially best-in-class oral panKRAS inhibitor targeting both ON and OFF states across multiple KRAS-mutant variants, as well as amplified wild type KRAS. First-in-human study anticipated in 2H2026. This marks the third ENSEM-discovered molecule to clear IND since 2024! For a small biotech, that's a remarkable milestone — and a testament to Team ENSEM's productivity, dedication, and drive. The patients who need us most are why we do this! 💙 #ENSEM #Oncology #KRAS #PrecisionOncology #FDA #Biotech
-
Biplab Das liked thisBiplab Das liked thisThis Memorial Day, Cancer Mukti Foundation honors and remembers the brave heroes who made the ultimate sacrifice for our nation. We are forever grateful for their courage and service. Wishing everyone a safe and meaningful Memorial Day. 🇺🇸
-
Biplab Das liked thisBiplab Das liked this#AgiosNews: The European Commission has granted marketing authorization for our first-in-class oral pyruvate kinase (PK) activator in adults for the treatment of anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. This decision makes it the only medicine approved in all European Union member states for this broad patient population. We are partnered with Avanzanite Bioscience, a regional specialty company, for commercialization and distribution of this medicine in Europe. Read our press release: https://bit.ly/49Of51j
Experience
-
BD Pharma Consulting
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Other similar profiles
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content